Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.4.2.3 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.4.8 (Delta)ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
AY.4.8 (Delta)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
AY.4.8 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.4.8 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.4.8 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.617.1 (Kappa)ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
B.1.617.1 (Kappa)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.617.1 (Kappa)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.617.1 (Kappa)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.617.1 (Kappa)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.4.3 (Delta)ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
AY.4.3 (Delta)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
AY.4.3 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.4.3 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.4.3 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.46.5 (Delta)ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
AY.46.5 (Delta)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
AY.46.5 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.46.5 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.46.5 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.4.1 (Delta)ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
AY.4.1 (Delta)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
AY.4.1 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.4.1 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.4.1 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
P.1.16 (Gamma)ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
P.1.16 (Gamma)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
P.1.16 (Gamma)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
P.1.16 (Gamma)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
P.1.16 (Gamma)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.10.3ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
BA.2.10.3ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
BA.2.10.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.10.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.10.3NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.4.5 (Delta)ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
AY.4.5 (Delta)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
AY.4.5 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.4.5 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.4.5 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.34.1 (Delta)ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
AY.34.1 (Delta)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
AY.34.1 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.34.1 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.34.1 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.4.2.1 (Delta)ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
AY.4.2.1 (Delta)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
AY.4.2.1 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.4.2.1 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used